Inovio

528 articles about Inovio

• INOVIO Expands INNOVATE Phase 3 for INO-4800, its DNA Vaccine Candidate for COVID-19, to include Colombia following Regulatory Authorization

  10/11/2021

  Authorization to conduct INNOVATE Phase 3 in Colombia builds on recent regulatory authorizations from Brazil, Philippines, and Mexico

• INOVIO to Present Three Posters at IDWeek 2021

  9/29/2021

  INOVIO will present three posters at IDWeek 2021, taking place virtually from September 29th - October 3rd .

• INOVIO to Present at Upcoming Investor Conferences in September 2021

  9/1/2021

  INOVIO, a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, announced that Dr. J. Joseph Kim, President and CEO, will present at the following investor conferences in September:.

• INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800

  8/26/2021

  INOVIO today announced that it has received regulatory authorization from Brazil's ANVISA to initiate the global Phase 3 segment of its Phase 2/3 trial, INNOVATE

• INOVIO and Advaccine Receive Regulatory Allowance for Two Heterologous Prime-Boost Clinical Trials in China Using INO-4800, INOVIO's COVID-19 DNA Vaccine Candidate

  8/9/2021

  INOVIO (NASDAQ:INO), today announced that it has received regulatory allowance for two clinical trials investigating heterologous boosting with INO-4800, its DNA vaccine candidate for COVID-19, through partner and trial-sponsor Advaccine Biopharmaceuticals Suzhou Co.,

• INOVIO Doses First Participant in Phase 2 Trial for its DNA Vaccine Against Middle East Respiratory Syndrome (MERS), a Coronavirus Disease

  8/4/2021

  INOVIO today announced that the company has dosed the first Phase 2 trial subject in its quest to develop the first vaccine against the Middle East Respiratory Syndrome (MERS).

• INOVIO to Report Second Quarter 2021 Financial Results on August 9, 2021

  7/26/2021

  INOVIO (NASDAQ: INO) announced today that second quarter 2021 financial results will be released after the market close on August 9, 2021.

• INOVIO Expands Partnership with Advaccine to Conduct Global Phase 3 Efficacy Trial of COVID-19 DNA Vaccine Candidate, INO-4800

  6/8/2021

  Phase 3 efficacy trial planned to commence this summer in areas of the world underserved by vaccines.

• INOVIO to Present at the Jefferies 2021 Virtual Healthcare Conference

  5/25/2021

  INOVIO a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, announced that Dr. Joseph Kim, President and CEO, is scheduled to participate in a fireside chat and 1x1 investor meetings at the Jefferies 2021 Virtual Healthcare Conference on Tuesday, June 1, 2021 at 2:00 PM EDT.

• INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors

  5/17/2021

  Dr. Dansey, Seagen's Chief Medical Officer, brings extensive expertise in immuno-oncology and drug development Appointment of industry leader in drug development expands the Board's diverse industry, clinical development, research and commercialization expertise

• INOVIO's Pan-COVID-19 Vaccine Candidate (INO-4802) Induces Broad Immunity Against Major Viral Variants in Preclinical Studies

  5/12/2021

  INOVIO's Pan-SARS-CoV-2 vaccine candidate INO-4802 is not matched to a single variant, unlike other variant vaccines in development; INO-4802 could potentially offer broader immune responses   [12-May-2021]   PLYMOUTH MEETING, Pa. , May 12, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology com

• INOVIO Reports First Quarter 2021 Financial Results

  5/10/2021

  INOVIOINOVIO, a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, reported financial results for the quarter ended March 31, 2021.

• INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA Vaccine

  5/10/2021

   INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced positive safety, tolerability and immunogenicity data from its placebo-controlled and blinded Phase 2 segment

• INOVIO to Report First Quarter 2021 Financial Results on May 10, 2021

  4/27/2021

   INOVIO (NASDAQ: INO) announced today that first quarter 2021 financial results will be released after the market close on May 10, 2021 . Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update regarding its DNA Medicines

• INOVIO Planning for ex-US Global Phase 3 Trial for INO-4800

  4/23/2021

  INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that it is planning for a predominantly ex-U.S. Phase 3 trial for its COVID-19 vaccine candidate, INO-4800

• INOVIO's COVID-19 Vaccine Candidate, INO-4800, Provides Broad Cross-reactive Immune Responses In Humans Against Variants of Concern

  4/15/2021

  Results in new study showed INO-4800 vaccine-induced neutralizing antibodies and T cell responses against UK, South African and Brazilian variant strains

• INOVIO Announces the Appointment of Michael Cordera As Executive Vice President & General Counsel

  3/15/2021

  INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the appointment of Michael Cordera as Executive Vice President and General Counsel.

• INOVIO to Present at Upcoming Investor Conferences in March

  3/4/2021

   INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced that Dr. J. Joseph Kim , President and CEO, along with other members of INOVIO management, will present at the following investor conference

• INOVIO Reports Fourth Quarter 2020 and Year-End Financial Results

  3/1/2021

  INOVIO (NASDAQ: INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today reported financial results for the quarter ended December 31, 2020.

• INOVIO Announces Positive Results from REVEAL 1, a Phase 3 Pivotal Trial Evaluating VGX-3100, its DNA-based HPV Immunotherapy for the Treatment of High-grade Precancerous Cervical Dysplasia Caused by HPV-16 and/or HPV-18

  3/1/2021

  INOVIO, (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer and HPV-associated diseases, today announced it met primary and secondary endpoints among all evaluable subjects for the REVEAL 1 trial